EQT Life Sciences
Investor profile
Venture capital
Also recorded as: EQT Lifesciences
Deals
19
distinct rounds
Companies
19
backed
Active span
2022–2026
5 yrs
Total round €
€1.2B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Andera Partners4
- Invest-NL3
- Novartis Venture Fund3
- Sofinnova Partners3
- Enterprise Ireland2
- Fountain Healthcare Partners2
- GIMV2
- imec.xpand2
- Innovation Industries2
- M Ventures2
- Novo Holdings2
- OrbiMed2
- Pfizer Ventures2
- Sanofi Ventures2
- SV Health Investors2
- Wellington Partners2
- 15th Rock1
- ABV Uni Fund1
- Adjuvant Capital1
- Advent Life Sciences1
- Aphelion1
- Asabys Partners1
- Ascenta Capital1
- ATEM1
- Atlantic Bridge1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Tubulis Technologies | Germany | 1 | €308M |
| Amolyt Pharma | France | 1 | €129M |
| SpliceBio | Spain | 1 | €118M |
| Artios | UK | 1 | €99M |
| ViCentra | Netherlands | 1 | €73M |
| Mosanna Therapeutics | Switzerland | 1 | €70M |
| Neurent Medical | Ireland | 1 | €63M |
| MinervaX | Denmark | 1 | €54M |
| Exciva | Germany | 1 | €51M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Phagenesis | UK | 1 | €39M |
| Cyted Health | UK | 1 | €38M |
| Xeltis | Switzerland | 1 | €32M |
| Onera Health | Netherlands | 1 | €30M |
| Ariceum Therapeutics | Germany | 1 | €25M |
| Perfuze | Ireland | 1 | €22M |
| LUMA Vision | Ireland | 1 | €20M |
| FundamentalVR | UK | 1 | €19M |
| Nua Surgical | Ireland | 1 | €6.5M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Tubulis Technologies | Series C | €308M | 2025-10 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| SpliceBio | Series B | €118M | 2025-06 |
| Artios | Series D+ | €99M | 2025-11 |
| ViCentra | Series D+ | €73M | 2025-09 |
| Mosanna Therapeutics | Series A | €70M | 2025-06 |
| Neurent Medical | Series C | €63M | 2026-02 |
| MinervaX | Other | €54M | 2023-10 |
| Exciva | Series B | €51M | 2026-01 |
| FoRx Therapeutics | Series A | €43M | 2025-12 |